A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor

This study is a multicenter, two-tumor, multi-cohort, dose-escalation and dose-expansion Phase Ib/II clinical trial of HB0025 combined with chemotherapy, consists of two phases: the dose escalation phase (Ib) and the dose expansion phase (II). 1. The dose escalation phase (Phase Ⅰb) The primary purpose is to determine the Maximum Tolerated Dose(MTD) and/or dose limiting toxicity (DLT) of HB0025 combined with chemotherapy. The dose escalation is carried out using the "3+3 dose escalation" principle. In the initial stage of the dose escalation process, the chemotherapy dose remains unchanged to

Trial Details

NCT ID
NCT06758557
Phase
PHASE1 / PHASE2
Sponsor
Huabo Biopharm Co., Ltd.
Status
RECRUITING
Cancer Type
Endometrial Cancer Uterine Cancer
Interventions
  • HB0025
  • Pemetrexed
  • Paclitaxel
  • Carboplatin
Locations (sample)
  • Baoding, Hebei, China|38.87288,115.46246
  • Harbin, Heilongjiang, China|45.75,126.65
  • Luoyang, Henan, China|34.67345,112.43684
  • Zhengzhou, Henan, China|34.75778,113.64861
  • Lianyungang, Jiangsu, China|34.59845,119.21556

Key Eligibility Criteria

  • Male or female, age between 18-75 years old (include 18- and 75-year-old);
  • Be able to fully understand and voluntarily sign the informed consent form, and be willing and able to comply with the clinical research and follow…
  • Dose escalation phase 3.1 Non-small cell lung cancer and meet all following conditions; 3.1.1 Non-small cell lung cancer (NSCLC) confirmed by histo…
  • 2 Endometrial cancer and meet all following conditions 3.2.1 Endometrial cancer confirmed by histology or cytology, the pathological types include …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Endometrial Cancer Uterine Cancer Trials on Trialify →